Generation Bio Co. (GBIO): Utang-utang marang kapitalisasi buku

Logo korporat perusahaan Generation Bio Corp (GBIO)

The development of Generation Bio Co. (GBIO) is driven by scientific breakthroughs rather than economic cycles, ensuring stable demand. The ratio of debt to book capitalization clearly demonstrates financial resilience, where 0.56 represents the current metric. Capitalization is based on the creation of non-viral therapies for rare pathologies, while operational risks are mitigated by engaging external research centers.

Generation Bio Co (GBIO) - Utang-utang marang nilai buku saka 04.07.2022 nganti 21.02.2026
Barang unggulan Generation Bio

For the biotech sector, Generation Bio Co. (GBIO) considers debt load assessment critical when scaling AI developments. This share of financial debt in the firm's balance sheet capitalization is calculated as the ratio of total liabilities to equity. The metric determines the ability of net assets to cover borrowed funds. For a company automating drug synthesis, a low ratio minimizes risks during costly clinical trials. The stability of this indicator confirms the fundamental resilience of the business.

Pesaing Generation Bio Co. (GBIO)

Utang-utang marang kapitalisasi buku TEM (Tempus AI Inc)|Utang-utang marang kapitalisasi buku qiagen.com QGEN|Utang-utang marang kapitalisasi buku IONS|RGEN - Utang marang aset resik|Utang-utang marang kapitalisasi buku RNA|CRSP (CRISPR) - Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku GeneDx Holdings Corp. (WGS)|Rasio utang marang nilai buku ultragenyx.com|Beam Therapeutics - Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku SRPT (Sarepta Therapeutics)|Rasio utang marang kapitalisasi buku Twist Bio|Rasio utang marang aset resik 10x TXG|Intellia Therapeutics - Utang-utang marang kapitalisasi buku|stoketherapeutics.com (STOK) - Utang-utang marang kapitalisasi buku|BLFS - Utang marang nilai buku|Wave Life Sciences Ltd (WVE) - Utang marang modal buku|MAZE: Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik SION|Prime Medicine, Inc. - Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku TSHA (tayshagtx.com)|QURE - Rasio utang marang kapitalisasi buku|MGTX - Rasio utang marang nilai buku|Utang marang nilai buku Regenxbio (RGNX)|SLDB - Rasio utang marang aset resik|Ocugen, Inc. (OCGN) - Utang-utang marang kapitalisasi buku|pacb.com (PACB) - Rasio utang marang kapitalisasi buku|BNTC: Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik DSGN|Rocket Pharmaceuticals Inc - Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku 4D Molecular Corp FDMT|Utang marang nilai buku Lexeo Therapeutics, Inc.|Rasio utang marang aset resik Korro Bio Inc. KRRO|EDIT: Utang-utang marang kapitalisasi buku|SLN: Utang marang nilai buku|Rasio utang marang kapitalisasi buku PRQR|Utang-utang marang nilai buku Codexis|SGMO: Utang marang nilai buku|Utang-utang marang aset resik Nautilus Biotechnology Inc|MGX: Utang-utang marang kapitalisasi buku|Utang marang aset resik Precision BioSciences Inc. (DTIL)|Utang-utang marang kapitalisasi buku Boundless Bio, Inc BOLD|Rasio utang marang kapitalisasi buku Exicure Inc. XCUR|Utang-utang marang kapitalisasi buku IMNN (Celsion Corporation)|PHIO: Utang-utang marang aset resik|Rasio utang marang kapitalisasi buku MBIO|TransCode Therapeutics, Inc. (RNAZ) - Utang-utang marang nilai buku|Utang-utang marang kapitalisasi buku Bionano Genomics Inc. (BNGO)|Rasio utang marang nilai buku APDN|Rasio utang marang kapitalisasi buku bluebird bio, Inc. BLUE|Rasio utang marang nilai buku immunoprecise.com (IPA)|Utang-utang marang kapitalisasi buku OMGA (Omega Therapeutics, Inc.)|Utang-utang marang kapitalisasi buku Singular Genomics Systems, Inc. OMIC|Utang-utang marang kapitalisasi buku RGLS|SYRS - Utang marang aset resik|Utang-utang marang kapitalisasi buku TBIO|TCON (traconpharma.com) - Utang-utang marang nilai buku|Rasio utang marang kapitalisasi buku Unity Biotechnology, Inc. (UBX)